Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2RqgN0v
via IFTTT